CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,007,160 | +3.5% | 145,609 | +27.6% | 0.01% | +7.7% |
| Q2 2023 | $3,872,431 | -4.4% | 114,130 | +1.4% | 0.01% | -7.1% |
| Q1 2023 | $4,049,909 | -19.5% | 112,560 | -0.2% | 0.01% | -22.2% |
| Q4 2022 | $5,028,343 | -43.8% | 112,819 | -64.6% | 0.02% | 0.0% |
| Q3 2022 | $8,951,646 | +29.9% | 318,438 | +24.6% | 0.02% | +38.5% |
| Q2 2022 | $6,891,919 | -34.7% | 255,632 | -17.5% | 0.01% | -13.3% |
| Q1 2022 | $10,553,677 | +71.9% | 309,846 | +95.0% | 0.02% | -6.2% |
| Q4 2021 | $6,141,000 | -30.2% | 158,922 | -2.5% | 0.02% | -36.0% |
| Q3 2021 | $8,800,000 | -42.5% | 162,983 | -64.4% | 0.02% | +13.6% |
| Q2 2021 | $15,312,000 | +149.6% | 457,902 | +53.8% | 0.02% | +15.8% |
| Q1 2021 | $6,134,000 | +3233.7% | 297,783 | +2736.0% | 0.02% | +1800.0% |
| Q4 2020 | $184,000 | – | 10,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |